ABBV vs MELI: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-09.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,632.52
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+45.0%).
MELI trades at a lower forward P/E
(43.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MELI |
| Current Price |
$197.69 |
$1,632.52 |
| Fair Value Estimate |
$210.22 |
$2,367.15 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$82.8B |
| Forward P/E |
83.3x
|
43.1x
|
| EV / EBITDA |
23.4x
|
22.5x
|
| Price / Sales |
5.7x
|
2.7x
|
| Price / FCF |
18.7x
|
7.2x
|
| Revenue Growth YoY |
+10.0%
|
+30.0%
|
| Gross Margin |
70.2%
|
45.5%
|
| Operating Margin |
26.7%
|
9.9%
|
| Return on Equity |
-361.6%
|
29.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
13.89%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
MercadoLibre, Inc. operates a leading e-commerce and fintech platform in Latin America, combining a dominant commerce marketplace with a rapidly growing fintech segment. The company benefits from a durable competitive moat driven by network effects, strong brand recognition, and a comprehensive logistics infrastructure. Despite a recent earnings growth decline of 15.6% in the most recent quarter,…
Accumulation Zones
| Metric |
ABBV |
MELI |
| Zone Low |
$157.66 |
$1,775.36 |
| Zone High |
$178.69 |
$2,012.08 |
| In Buy Zone? |
No
|
Yes
|